Key Details
Price
$2.38Annual ROE
-91.86%Beta
1.81Events Calendar
Next earnings date:
Mar 20, 2025Recent quarterly earnings:
Nov 7, 2024Recent annual earnings:
Mar 20, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Achieves Major Milestone with FDA Submission for its Groundbreaking 12-Lead ECG Synthesis Software.
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference.
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology.
HeartBeam, Inc. (NASDAQ:BEAT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Rob Eno - Chief Executive Officer Branislav Vajdic - President and Founder Tim Cruickshank - Chief Financial Officer Conference Call Participants Operator Greetings, and welcome to the HeartBeam Third Quarter 2024 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Appoints Robert Eno as Chief Executive Officer in Preparation for US Commercialization.
- Data continue to support revumenib's potential to enhance current standard of care agents - - 96% CRc (23 of 24 pts) observed in BEAT AML trial exploring revumenib in combination with venetoclax/azacitidine in newly diagnosed mNPM1 or KMT2Ar AML - - 52% CRc (14 of 27 pts) observed in AUGMENT-102 trial of revumenib in combination with fludarabine-cytarabine in acute leukemia patients with R/R mNPM1, NUP98r or KMT2Ar - WALTHAM, Mass. , June 14, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated data from multiple combination trials of revumenib, the Company's potent, selective, small molecule menin inhibitor, in patients with acute leukemias.
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam's Artificial Intelligence Algorithm Combined with Vectorcardiography (VCG) Outperforms Expert Cardiologists in Detecting Arrhythmias.
HeartBeam, Inc. (NASDAQ: BEAT) Q1 2024 Earnings Conference Call on May 9, 2024 at 4:30 PM ET with Company Participants Branislav Vajdic, Rob Eno, Rick Brounstein, and Brooks Hamilton, as well as Conference Call Participants Leo Carpio. Thank you for joining us for the HeartBeam First Quarter 2024 Financial Results Conference Call.
HeartBeam showcases successful outcomes in utilizing its artificial intelligence technology to identify irregular heart rhythms.
HeartBeam (NASDAQ: BEAT ) just reported results for the fourth quarter of 2023. HeartBeam reported earnings per share of -13 cents.
FAQ
- What is the ticker symbol for HeartBeam?
- Does HeartBeam pay dividends?
- What sector is HeartBeam in?
- What industry is HeartBeam in?
- What country is HeartBeam based in?
- When did HeartBeam go public?
- Is HeartBeam in the S&P 500?
- Is HeartBeam in the NASDAQ 100?
- Is HeartBeam in the Dow Jones?
- When was HeartBeam's last earnings report?
- When does HeartBeam report earnings?
- Should I buy HeartBeam stock now?